Box Office

Choi Min-sik and Han So-hee’s ‘Intern’ Tops the Box Office for Three Consecutive Days

Cumulative Attendance Exceeds 180,000 No. 2 'Odyssey'

Gim Ga Yeong
2026-09-19 16:21:56
[Edaily Starin Gim Ga Yeong Reporter] The movie "The Intern," starring actors Choi Min-sik and Han So-hee, has topped the box office for the third consecutive day.
Poster for the movie “The Intern” (Photo courtesy of Warner Bros. Korea)
According to data from the Korean Film Council’s integrated computer network for movie theater ticket sales on the 19th, “The Intern” attracted 61,142 viewers on the 18th alone, securing the No. 1 spot at the box office. Its cumulative audience count stands at 189,862.
Released on the 16th, “The Intern” is a Korean reinterpretation of the 2015 Hollywood film of the same name starring Robert De Niro and Anne Hathaway. It tells the story of what unfolds when Ki-ho (played by Choi Min-sik), a “silver intern” with 37 years of experience, joins the company of Seon-woo (played by Han So-hee), the CEO of a fashion startup. Director Kim Do-young, known for “Kim Ji-young, Born 1982” and “If We,” directed the film.
“Odyssey” took second place. “Odyssey” drew 55,192 viewers, securing the number two spot. Its cumulative audience stands at 11,016,040.
“Obsession” took third place, drawing 31,449 viewers. Its cumulative audience stands at 601,695.

Economy

Corporation

IT·Science

Economy

[VC's Pick] The AI That Played a Match Against Lee Sedol 9-dan… Enhance Secures 51.2 Billion Investment

This week (September 14–18), startups in various fields—including medical artificial intelligence (AI), content solutions, and content tech—secured investments from venture capital (VC) firms and acce…
2026-09-19 09:21:04

Corporation

Kang Seong-min, CEO of PeopleBio, Inc.: “Full-Scale Launch of LDT and Diagnostic Kit Business in the U.S. … Revenue to Become Apparent Starting Next Year”

“Building on our designation as an innovative medical device by the U.S. Food and Drug Administration (FDA), we plan to establish a local subsidiary within this year. Next year, we will launch laborat…
2026-09-19 08:07:02

IT·Science

Opacalim Clinical Trials Paused… A Closer Look at the Preconditions for SK BIOPHARMACEUTICALS’s 2.3 Trillion Won Deal

SK BIOPHARMACEUTICALS(326030)has drawn attention by repeatedly emphasizing that the deal to acquire “Opacalym” (BHV-7000), a new drug candidate for epilepsy, from the U.S. biotech company Biohaven is …
2026-09-19 08:41:01